

Contact: James Talton, CEO

Location: Alachua, FL

Email: jtalton@nanotherapeutics.com

Tel: (386) 462-9663

Website: <http://www.nanotherapeutics.com>



Company Profile

Industry Sector: Pharmaceutical and Biologics

Company Overview: Nanotherapeutics is a privately-owned Florida company with a proven track record in GMP manufacturing and preclinical to clinical product development. Nanotherapeutics is pioneering the applications of novel particle delivery technologies in the development and manufacturing of novel pharmaceutical and biomedical products. The company employs several platform technologies to manipulate and enhance the properties of drugs.

Nanotherapeutics' technologies address these issues by:

- Providing non-invasive routes of administration, i.e. oral or inhaled.
- Enhancing the systemic absorption (bioavailability) of compounds.

Target Market(s): Nanotherapeutics partners for marketing and distribution of its pharmaceutical and biologic products to the public, including hospital-based therapies and doctor-prescribed drug regimens.

Key Value Drivers

Technology*: The key benefit of our NanoBUP™ rapid-release swallowed capsule product is that it improves the ability of the body to efficiently absorb buprenorphine with less variability than sublingual administration.

- NanoBUP™ capsule bioavailability 5-7x compared to buprenorphine solution
- Potential to increase use, including withdrawal and detoxification in opiate-abusers.

Competitive Advantage: Nanotherapeutics' technologies can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.

Plan & Strategy: Nanotherapeutics has 1 FDA approved injectable product and a pipeline of partnered and internal programs. Nanotherapeutics partners for marketing and distribution.

*Technology funded by NIDA and being commercialized under the NIH-CAP

Management

Leadership:

James D. Talton, Ph.D., President & CEO

Dennis Tomisaka, M.S., MBA, V.P., Operations & Product Dev.

Barbel Eppler, Ph.D., V.P., Preclinical & QA

James Kirk, Ph.D., MBA, V.P., Research and Development

John Abernethy, M.D., Medical Director

Dennis Kristof, CMA, MBA, Controller

Board of Directors:

Weaver H. Gaines, 35 years of executive, legal, and entrepreneurial experience

Robert Hennessey, executive with Penwest, Abbott, SmithKline, and Merck.

James M. Matthew, experienced financial executive, CFO of Jesup & Lamont.

James R. Butler, ex-President of Alza International, Advisor to Capnia, Reliant

Sean McConnell, MSM, LLP, and Dir. of HR, Modern Business Associates, Inc.

James Fitz-Gerald, Ph.D., Asst. Professor, Dept. of Materials Sci. & Eng., UVA

Product Pipeline

Current Products

Medical Devices	R&D	Animal Studies	510(k)	Market	Partner
Origen DBM™	[Progress bar]				Blackstone / Orthofix

Product Pipeline

Pharmaceuticals	R&D	Pre-Clin	Phase 1	Phase 2	Phase 3	NDA	Market	Partner
NanoDOX™	[Completed]		[In Progress]					
NanoBUP™	[Completed]		[In Progress]					
NanoGENT™	[Completed]		[In Progress]					
Oral Internal Compound 1	[Completed]							

Legend: [Orange] Completed [Yellow] In Progress